UnknownNot Applicable

Latin America Registry on WatchmanTM Outcomes in Real Life

Venezuela500 participantsStarted 2018-10-01

Plain-language summary

Left atrial appendage (LAA) occlusion with WatchmanTM has emerged as viable alternative to anticoagulation therapy in randomized controlled trials. The device has FDA approved since 2015 and the firsts Latin American cases were performed in 2012. However, there is no real world data from Latin American experience in terms of success and outcomes.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients who were eligible for a WatchmanTM device implantation according to current international and local guidelines and per physician and institution discretion. Exclusion Criteria: * Patient who were currently enrolled in another investigational study or registry that would directly interfere with the current study aims.

What they're measuring

Incidence of Periprocedural complications

Timeframe: At implant

Incidence of Stroke

Timeframe: 6 months follow up

Incidence of Death

Timeframe: 6 months follow up

Trial details

NCT IDNCT03651323

SponsorCentro Medico Docente la Trinidad

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2018-11-01

View on ClinicalTrials.gov More Atrial Fibrillation trials